文献速递肝病

自身免疫性肝炎的治疗应答与无临床事件生存:加拿大一项多中心队列研究

Treatment response and clinical event-free survival in autoimmune hepatitis: A Canadian multicentre cohort study.
PubMed 文献 · J Hepatol · 2024-03-24

该研究在加拿大11个中心纳入691例自身免疫性肝炎患者,中位随访6年,评估治疗应答及临床事件预测因素。结果显示持续转氨酶升高而非IgG与较差长期结局相关,生化应答与长期生存和初始泼尼松剂量无关。

要点

  • 持续ALT升高(HR 1.07)和AST升高(HR 1.13)与临床事件风险增加相关,IgG无显著关联。
  • 基线肝硬化患者临床事件风险升高(HR 3.67),ALT正常化几率降低(OR 0.52)。
  • 初始泼尼松剂量未预测平均ALT下降,生化应答与长期生存亦与之无关。

核心结论

  • 在自身免疫性肝炎患者中,持续升高的转氨酶值而非IgG与较差的长期结局相关。
  • 生化应答和长期生存与初始泼尼松剂量无关。

研究设计与样本

  • 研究评估了加拿大11个中心自身免疫性肝炎患者的临床病程,共691例,中位年龄49岁,女性占75.4%,中位随访6年(第25至75百分位,2.5至11年)。
  • 生化变化采用线性混合效应和逻辑回归分析,临床结局采用时变Cox比例风险模型和里程碑分析进行动态建模。

主要发现

  • 随访期间共发生118例临床事件,63.8%的患者在12个月内实现丙氨酸氨基转移酶(ALT)正常化。
  • 诊断时年龄较大(OR 1.19,95%CI 1.06-1.35)和女性(OR 1.94,95%CI 1.18-3.19)与6个月时ALT正常化相关,基线肝硬化状态与12个月时正常化几率降低相关(OR 0.52,95%CI 0.33-0.82)。
  • 基线总胆红素、氨基转移酶和IgG值以及初始泼尼松剂量未预测平均ALT下降。
  • 基线时年龄较大(HR 1.25,95%CI 1.12-1.40)、诊断时肝硬化(HR 3.67,95%CI 2.48-5.43)和基线总胆红素升高(HR 1.36,95%CI 1.17-1.58)增加临床事件风险。
  • ALT持续升高(HR 1.07,95%CI 1.00-1.13)和天冬氨酸氨基转移酶持续升高(HR 1.13,95%CI 1.06-1.21)与临床事件风险较高相关,而IgG持续升高(HR 1.01,95%CI 0.95-1.07)无显著关联;6个月时ALT较高与较差的无临床事件生存相关。

临床怎么用

  • 作者认为,研究结果挑战了IgG作为治疗应答标志物的作用,以及IgG正常化是否应继续作为生化缓解定义的重要组成部分。
  • 作者指出,基线疾病严重程度标志物可能不能预测早期治疗应答,初始泼尼松剂量对于实现氨基转移酶正常化可能不太相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Treatment outcomes for people living with autoimmune hepatitis (AIH) are limited by a lack of specific therapies, as well as limited well-validated prognostic tools and clinical trial endpoints. We sought to identify predictors of outcome for people living with AIH. METHODS: We evaluated the clinical course of people with AIH across 11 Canadian centres. Biochemical changes were analysed using linear mixed-effect and logistic regression. Clinical outcome was dynamically modelled using time-varying Cox proportional hazard modelling and landmark analysis. RESULTS: In 691 patients (median age 49 years, 75.4% female), with a median follow-up of 6 years (25th-75th percentile, 2.5-11), 118 clinical events occurred. Alanine aminotransferase (ALT) normalisation occurred in 63.8% of the cohort by 12 months. Older age at diagnosis (odd ratio [OR] 1.19, 95% CI 1.06-1.35) and female sex (OR 1.94, 95% CI 1.18-3.19) were associated with ALT normalisation at 6 months, whilst baseline cirrhosis status was associated with reduced chance of normalisation at 12 months (OR 0.52, 95% CI 0.33-0.82). Baseline total bilirubin, aminotransferases, and IgG values, as well as initial prednisone dose, did not predict average ALT reduction. At baseline, older age (hazard ratio [HR] 1.25, 95% CI 1.12-1.40), cirrhosis at diagnosis (HR 3.67, 95% CI 2.48-5.43), and elevated baseline total bilirubin (HR 1.36, 95% CI 1.17-1.58) increased the risk of clinical events. Prolonged elevations in ALT (HR 1.07, 95% CI 1.00-1.13) and aspartate aminotransferase (HR 1.13, 95% CI 1.06-1.21), but not IgG (HR 1.01, 95% CI 0.95-1.07), were associated with higher risk of clinical events. Higher ALT at 6 months was associated with worse clinical event-free survival. CONCLUSION: In people living with AIH, sustained elevated aminotransferase values, but not IgG, are associated with poorer long-term outcomes. Biochemical response and long-term survival are not associated with starting prednisone dose. IMPACT AND IMPLICATIONS: Using clinical data from multiple Canadian liver clinics treating autoimmune hepatitis (AIH), we evaluate treatment response and clinical outcomes. For the first time, we apply mixed-effect and time-varying survival statistical methods to rigorously examine treatment response and the impact of fluctuating liver biochemistry on clinical event-free survival. Key to the study impact, our data is 'real-world', represents a diverse population across Canada, and uses continuous measurements over follow-up. Our results challenge the role of IgG as a marker of treatment response and if normalisation of IgG should remain an important part of the definition of biochemical remission. Our analysis further highlights that baseline markers of disease severity may not prognosticate early treatment response. Additionally, the initial prednisone dose may be less relevant for achieving aminotransferase normalisation. This is important for patients and treating clinicians given the relevance and importance of side effects.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Plagiannakos CG, Hirschfield GM, Lytvyak E, et al. Treatment response and clinical event-free survival in autoimmune hepatitis: A Canadian multicentre cohort study. J Hepatol. 2024. PMID: 38527524. doi:10.1016/j.jhep.2024.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。